• AAPL 194.8499
  • TSLA 241.7314
  • AMZN 147.095
  • BTC-USD 43447.7188
  • ETH-USD 2336.4297
  • EURUSD 1.0808
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. ABBV.US

AbbVie Inc (ABBV NYSE) stock market data APIs

$144.79 -1.59(-1.1%) as of December 6, 2023

AbbVie Inc Financial Data Overview

146.38
144.79
-
147.07
144.73
128.2406-162.7487
259 835 M
40.4313
1 766 M
55 138 M
2.95
0.0424
0.449
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ABBV',
Type: 'Common Stock',
Name: 'AbbVie Inc',
Exchange: 'NYSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG0025Y4RY4',
ISIN: NULL,
CUSIP: NULL,
CIK: '1551152',
EmployerIdNumber: '32-0375147',
FiscalYearEnd: 'December',
IPODate: '2013-01-02',
InternationalDomestic: 'International/Domestic',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

AbbVie Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 55 138 M
  • EBITDA 27 993 M
  • Earnings Per Share 3.64
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get AbbVie Inc Earnings via APIs

  • Latest Release 2023-10-27
  • EPS/Forecast 2.86

Get AbbVie Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get AbbVie Inc latest news via APIs

AbbVie acquiring Cerevel Therapeutics in $8.7B deal

AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonz...

AbbVie Is Buying Cerevel Therapeutics, Which I Recommended Last Month. Now What?

Cerevel Therapeutics Holdings is a stock I last wrote about on Nov. 6. At that time, my bottom-line strategy for the drug developer was as follows: "Aggressive traders could begin to probe the long side of CERE on a dip to $25, risking to $21. Continue reading
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com